+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report

  • PDF Icon

    Report

  • 146 Pages
  • February 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227788
The global market for Inflammatory Bowel Disease (IBD) Therapeutics was valued at US$24.3 Billion in 2024 and is projected to reach US$32.8 Billion by 2030, growing at a CAGR of 5.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Inflammatory Bowel Disease (IBD) Therapeutics - Key Trends and Drivers

The growth in the IBD therapeutics market is driven by several factors, including the increasing prevalence of IBD, technological innovations, and greater awareness and diagnosis of the condition. The rising incidence of IBD globally, particularly in developed regions, is significantly expanding the patient population in need of effective treatments. Technological advancements in biologic therapies and the development of biosimilars are reducing treatment costs and making advanced therapies more accessible. The integration of precision medicine into IBD treatment protocols is leading to more effective and personalized therapeutic approaches, improving patient outcomes and satisfaction. Additionally, the adoption of digital health technologies is facilitating better disease management and patient engagement, driving adherence to treatment plans. Regulatory support for novel therapies and expedited approval processes for new drugs are also contributing to market growth. Moreover, ongoing clinical trials and research into the pathophysiology of IBD are paving the way for the development of next-generation therapeutics, promising even more effective and targeted treatment options in the future. These combined factors underscore the dynamic and rapidly evolving nature of the IBD therapeutics market.

Technological advancements and ongoing research are significantly impacting the IBD therapeutics landscape. The development of novel biologic therapies and biosimilars has expanded the range of treatment options available to patients. These therapies, including TNF inhibitors, integrin inhibitors, and interleukin inhibitors, offer targeted mechanisms of action that help control inflammation more effectively and with fewer side effects than conventional treatments. Additionally, advancements in precision medicine and pharmacogenomics are enabling more personalized treatment strategies, optimizing therapeutic outcomes based on individual patient profiles. Non-invasive diagnostic tools, such as advanced imaging techniques and biomarkers, are improving the ability to monitor disease activity and treatment response, allowing for more timely and accurate adjustments to therapeutic regimens. Furthermore, digital health technologies, including mobile health apps and telemedicine, are enhancing patient management and adherence to treatment plans by facilitating better communication between patients and healthcare providers.

Inflammatory Bowel Disease (IBD) therapeutics encompasses a range of treatments designed to manage and alleviate the symptoms of chronic inflammatory conditions of the gastrointestinal tract, primarily Crohn's disease and ulcerative colitis. These conditions cause severe inflammation, leading to symptoms such as abdominal pain, diarrhea, rectal bleeding, and weight loss. The primary goal of IBD therapeutics is to induce and maintain remission, reduce inflammation, and improve patients' quality of life. Treatment options include aminosalicylates, corticosteroids, immunomodulators, biologics, and, more recently, small molecule drugs. Biologics, which target specific components of the immune system, have revolutionized IBD treatment, providing relief for patients who do not respond to traditional therapies. However, the complexity of IBD, with its varying presentations and patient responses, necessitates a personalized approach to treatment.

Report Scope

The report analyzes the Inflammatory Bowel Disease (IBD) Therapeutics market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below.

Segments

Drug Class (TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors, Other Drug Classes); Type (Crohn's Disease, Ulcerative Colitis); Route of Administration (Injectable, Oral); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the TNF Inhibitor Drugs segment, which is expected to reach US$14 Billion by 2030 with a CAGR of a 5.9%. The Anti-Integrin Drugs segment is also set to grow at 4.9% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $6.3 Billion in 2024, and China, forecasted to grow at an impressive 8.2% CAGR to reach $7.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Inflammatory Bowel Disease (IBD) Therapeutics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Inflammatory Bowel Disease (IBD) Therapeutics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Inflammatory Bowel Disease (IBD) Therapeutics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Aclaris Therapeutics, Amgen, Inc., Cosmo Pharmaceuticals, Dr. Falk Pharma GmbH, Evotec SE and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 69 companies featured in this Inflammatory Bowel Disease (IBD) Therapeutics market report include:

  • Aclaris Therapeutics
  • Amgen, Inc.
  • Cosmo Pharmaceuticals
  • Dr. Falk Pharma GmbH
  • Evotec SE
  • F. Hoffmann-La Roche AG
  • Formycon
  • Gilead Sciences, Inc.
  • InDex Pharmaceuticals Holding AB
  • Kobiolabs

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Inflammatory Bowel Disease (IBD) Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of IBD Throws the Spotlight on Growing Therapeutic Needs
  • Technological Innovations in Biologic Therapies Propel Growth in IBD Treatment Options
  • Increasing Adoption of Biosimilars Expands Addressable Market Opportunity
  • Advancements in Precision Medicine Strengthen Business Case for Personalized IBD Therapies
  • Integration of Digital Health Technologies Drives Adoption of Remote Patient Management Solutions
  • Enhanced Non-Invasive Diagnostic Tools Generates Demand for Advanced Monitoring Techniques
  • Growing Awareness and Early Diagnosis of IBD Improves Patient Outcomes
  • Ongoing Clinical Trials and Research into Pathophysiology to Shape Future Therapeutics
  • Patient Demand for Minimally Invasive Treatments Drives Adoption of New Drug Delivery Methods
  • Increasing Investment in Healthcare Infrastructure Expands Addressable Market Opportunity
  • Shift towards Personalized Medicine Generates Demand for Tailored IBD Therapeutic Approaches
  • Rising Incidence of IBD in Developed Regions Strengthens Business Case for Market Expansion
  • Development of Next-Generation Therapeutics Create New Market Opportunities
  • Economic and Social Impact of IBD Propels Demand for Effective Long-Term Treatments
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Inflammatory Bowel Disease (IBD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 3: World Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 4: World 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for TNF inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 6: World Historic Review for TNF inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 7: World 15-Year Perspective for TNF inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Anti-integrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 9: World Historic Review for Anti-integrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 10: World 15-Year Perspective for Anti-integrin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 12: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 13: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Aminosalicylates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 15: World Historic Review for Aminosalicylates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 16: World 15-Year Perspective for Aminosalicylates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for IL inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 18: World Historic Review for IL inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 19: World 15-Year Perspective for IL inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for JAK inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 21: World Historic Review for JAK inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 22: World 15-Year Perspective for JAK inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 24: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 25: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Crohn`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 27: World Historic Review for Crohn`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 28: World 15-Year Perspective for Crohn`s Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 30: World Historic Review for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 31: World 15-Year Perspective for Ulcerative Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 32: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 33: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 34: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 35: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 36: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 37: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 38: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 39: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 40: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 41: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 42: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 43: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 44: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 45: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 46: World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Aclaris Therapeutics
  • Amgen, Inc.
  • Cosmo Pharmaceuticals
  • Dr. Falk Pharma GmbH
  • Evotec SE
  • F. Hoffmann-La Roche AG
  • Formycon
  • Gilead Sciences, Inc.
  • InDex Pharmaceuticals Holding AB
  • Kobiolabs

Table Information